AVEO Pharmaceuticals Inc. (AVEO)’s Financial Results Comparing With Intra-Cellular Therapies Inc. (NASDAQ:ITCI)

This is a contrast between AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) and Intra-Cellular Therapies Inc. (NASDAQ:ITCI) based on their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AVEO Pharmaceuticals Inc. 5.99M 18.77 4.21M -0.05 0.00
Intra-Cellular Therapies Inc. N/A 0.00 154.48M -2.82 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of AVEO Pharmaceuticals Inc. and Intra-Cellular Therapies Inc.

Profitability

Table 2 provides us AVEO Pharmaceuticals Inc. and Intra-Cellular Therapies Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
AVEO Pharmaceuticals Inc. 70.28% 51.6% -83.7%
Intra-Cellular Therapies Inc. 0.00% -45.8% -41.3%

Risk & Volatility

AVEO Pharmaceuticals Inc. has a 1.25 beta, while its volatility is 25.00% which is more volatile than S&P 500. Intra-Cellular Therapies Inc.’s 1.39 beta is the reason why it is 39.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of AVEO Pharmaceuticals Inc. are 1.5 and 1.5 respectively. Its competitor Intra-Cellular Therapies Inc.’s Current Ratio is 9.6 and its Quick Ratio is 9.6. Intra-Cellular Therapies Inc. can pay off short and long-term obligations better than AVEO Pharmaceuticals Inc.

Analyst Recommendations

Recommendations and Ratings for AVEO Pharmaceuticals Inc. and Intra-Cellular Therapies Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AVEO Pharmaceuticals Inc. 0 2 1 2.33
Intra-Cellular Therapies Inc. 0 0 2 3.00

AVEO Pharmaceuticals Inc. has a consensus target price of $2, and a 185.76% upside potential. Intra-Cellular Therapies Inc. on the other hand boasts of a $27 average target price and a 115.83% potential upside. The information presented earlier suggests that AVEO Pharmaceuticals Inc. looks more robust than Intra-Cellular Therapies Inc. as far as analyst belief.

Insider & Institutional Ownership

Institutional investors owned 32.4% of AVEO Pharmaceuticals Inc. shares and 79.4% of Intra-Cellular Therapies Inc. shares. Insiders owned 0.3% of AVEO Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 3.8% of Intra-Cellular Therapies Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVEO Pharmaceuticals Inc. -12.31% -20.19% 35.34% -57.09% -64.05% -50.12%
Intra-Cellular Therapies Inc. -8.71% -2.22% -8.98% -31.67% -40.49% 8.52%

For the past year AVEO Pharmaceuticals Inc. had bearish trend while Intra-Cellular Therapies Inc. had bullish trend.

Summary

On 7 of the 11 factors AVEO Pharmaceuticals Inc. beats Intra-Cellular Therapies Inc.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.